NHL
Conditions
Brief summary
Assessment of the Safety and efficacy of Administering decitabin plus R-GDP to NHL patients
Detailed description
RR NHL patients will be treated with decitabin plus R-GDP , safety and efficacy will be assessed.
Interventions
DRUGDecitabine and R-GDP
Decitabine and R-GDP
Sponsors
Beijing Immunochina Medical Science & Technology Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Relapsed or refractory Non-Hodgkin's lymphoma(NHL) patiens. 2. Eastern Cooperative Oncology Group(ECOG) score 0-2 3. Expected survival \>3 months 4. Measurable disease.
Exclusion criteria
1. Patients who needs treatment with immunosuppressive agents 2. Hematosepsis or Uncontrolled active infection 3. History of epilepsy or other CNS disease. 4. Active hepatitis B , hepatitis C or HIV infection or any other uncontrolled active infection. 5. Pregnancy or breast-feeding women. 6. Any uncontrolled medical disorders that the researchers considered are not suitable to participate the clinical trial. 7. Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluatio
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | 2 years | Overall survival |
Countries
China
Contacts
Primary Contactxian lu, Dr
Outcome results
None listed